Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises on Harbour BioMed's US$220 million Hong Kong IPO and Listing

  • en
  • zh
  • Language options

10 December 2020

Clifford Chance advises on Harbour BioMed's US$220 million Hong Kong IPO and Listing

Leading international law firm Clifford Chance has advised the joint sponsors Morgan Stanley, Bank of America Securities, CLSA and joint global coordinators CICC and Credit Suisse on biopharmaceutical company Harbour BioMed's US$220 million IPO and listing on the main board of the Hong Kong Stock Exchange (SEHK). Shanghai-based Harbour BioMed engages in the discovery and development of novel antibody therapies in immunology and oncology.

Partner Fang Liu commented: "We continue to see great momentum in biotech company IPOs under the SEHK' ground-breaking Chapter 18A regime and look forward to working with more high quality issuers like Harbour BioMed."

Fang and partner Christine Xu co-led on the deal, with support from a team in Hong Kong, Beijing and Shanghai including senior associates Sheng Chen and Samson Chan, and associates Alex Feng, Jiawei Zhao, Dichun Duan and Jingxuan Liu.

Clifford Chance's market leading Greater China IPO practice continues to advise on the equity fundraising of the most innovative biotech and healthcare companies, including Hygeia Healthcare, Genetron and Ascentage Pharma.

高伟绅参与和铂医药2.2亿美元香港首次公开发行和上市

国际领先律师事务所高伟绅就生物制药企业和铂医药2.2亿美元首次公开发行和香港联交所主板上市,担任联席保荐人摩根士丹利、美银、中信里昂及联席全球协调人中金公司和瑞信的国际法律顾问。和铂医药总部位于上海,从事研究及开发免疫与肿瘤疾病领域的差异化抗体疗法。

合伙人方刘律师表示:“我们看到生物科技公司通过香港联交所第18A章赴港上市的势头持续强劲,并期待与更多像和铂医药一样的行业翘楚合作。”

本交易由方刘律师和合伙人许文嘉律师共同领导,由香港、北京和上海办公室包括陈盛、陈澍森、冯也威、赵家炜、段棣淳和刘靖轩在内的律师团队提供支持。

高伟绅市场领先的香港资本市场团队持续为最具创新性的生物科技和医疗健康企业的股权融资提供法律服务,其中包括海吉亚医疗泛生子亚盛医药